Literature DB >> 3341861

Pregnancy and paroxysmal nocturnal hemoglobinuria.

P Solal-Céligny1, G Tertian, H Fernandez, J C Pons, T Lambert, Y Najean, J P Clauvel, E Papiernik, G Tchernia.   

Abstract

Our study concerns eight pregnancies, six of which were successful, in four patients with paroxysmal nocturnal hemoglobinuria (PNH). Several complications of PNH during pregnancy were prevented: chronic anemia, folate and iron deficiency, and deep-vein thrombosis. During puerperium, acute hemolytic crises, most probably triggered by delivery, were observed in two patients. Thrombotic complications could be prevented by early initiation of an anticoagulant therapy after delivery. The only neonatal complication, observed in two cases, was isoimmune hemolytic anemia related to the multiple blood transfusions received before and during pregnancy. These results show that successful pregnancies are possible in women with PNH provided that both the obstetricians and physicians in charge monitor the pregnancies closely.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3341861     DOI: 10.1001/archinte.1988.00380030099019

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  2 in total

1.  Paroxysmal nocturnal hemoglobinuria and pregnancy before the eculizumab era: the French experience.

Authors:  Sophie de Guibert; Régis Peffault de Latour; Nathalie Varoqueaux; Hélène Labussière; Bernard Rio; Dominique Jaulmes; Jean-Richard Eveillard; Stéphanie Dulucq; Anne-Marie Stoppa; Didier Bouscary; François Girodon; Bernard Bonnotte; Djamila Laskri; Gérard Socié; Thierry Lamy
Journal:  Haematologica       Date:  2011-05-23       Impact factor: 9.941

Review 2.  Successful anticoagulant therapy for two pregnant PNH patients, and prospects for the eculizumab era.

Authors:  Yasuyoshi Morita; Jun-ichi Nishimura; Takahiro Shimada; Hirokazu Tanaka; Kentaro Serizawa; Yasuhiro Taniguchi; Mitsuhiro Tsuritani; Yuzuru Kanakura; Itaru Matsumura
Journal:  Int J Hematol       Date:  2013-03-02       Impact factor: 2.490

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.